Emulating Target Clinical Trials of Radical Nephrectomy With or Without Lymph Node Dissection for Renal Cell Carcinoma

被引:10
作者
Bacic, Janine [1 ,2 ,3 ]
Liu, Tao [2 ,4 ]
Thompson, R. Houston [5 ]
Boorjian, Stephen A. [5 ]
Leibovich, Bradley C. [5 ]
Golijanin, Dragan [6 ,7 ]
Gershman, Boris [8 ]
机构
[1] Adv CTR, Providence, RI USA
[2] Brown Univ, Sch Publ Hlth, Ctr Far Evidence Synth Hlth, Providence, RI 02912 USA
[3] Rhode Isl Hosp, Lifespan Biostat Core, Providence, RI USA
[4] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI 02912 USA
[5] Mayo Clin, Dept Urol, Rochester, MN USA
[6] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA
[7] Miriam Hosp, Rhode Isl Hosp, Div Urol, Providence, RI 02906 USA
[8] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
CYTOREDUCTIVE NEPHRECTOMY; SURVIVAL; THERAPY; RISK;
D O I
10.1016/j.urology.2020.01.039
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To emulate two target clinical trials of radical nephrectomy (RN) with lymph node dissection (LND) vs radical nephrectomy alone. Methods: Using the National Cancer Database, we separately emulated an index trial of patients with cT1-3cN0cM0 renal cell carcinoma (RCC), designed to resemble EORTC 30881 (“index trial emulation”), and a hypothetical trial of patients at increased risk for lymph node metastases with cT1-4cN0-1cM0 RCC (“high-risk trial emulation”). A propensity score for LND was estimated using preoperative features (Model 1) or preoperative and pathologic features (Model 2). The associations of LND with overall survival (OS) were estimated using Cox regression with stabilized inverse probability weights. Results: A total of 67,388 patients were included in the index trial emulation. Median follow-up was 49.2 (interquartile range 27.2-74.3) months. LND was not associated with improved OS when adjusting using either Model 1 (hazard ratio [HR] 1.26; 95% confidence interval [CI] 1.20-1.33; P <.0001) or Model 2 (HR 1.13; 95% CI 1.07-1.20; P <.0001). A total of 69,477 patients were included in the high-risk trial emulation. Median follow-up was 48.6 (interquartile range 26.6-73.8) months. LND was not associated with improved OS when adjusting using either Model 1 (HR 1.24; 95% CI 1.18-1.30; P <.0001) or Model 2 (HR 1.09; 95% CI 1.04-1.16; P = .001). In sensitivity analyses, LND was not associated with improved OS across cN stage, pT stage, tumor grade, histologic subtype, or probability of pN1 disease. Conclusion: In observational analyses, that emulate target trials representing EORTC 30881 and a trial of LND in high-risk RCC, LND was not associated with improved OS. © 2020 Elsevier Inc.
引用
收藏
页码:98 / 105
页数:8
相关论文
共 22 条
  • [1] Systematic Review of Adrenalectomy and Lymph Node Dissection in Locally Advanced Renal Cell Carcinoma
    Bekema, Hendrika J.
    MacLennan, Steven
    Imamura, Mari
    Lam, Thomas B. L.
    Stewart, Fiona
    Scott, Neil
    MacLennan, Graeme
    McClinton, Sam
    Griffiths, T. R. Leyshon
    Skolarikos, Andreas
    MacLennan, Sara J.
    Sylvester, Richard
    Ljungberg, Borje
    N'Dow, James
    [J]. EUROPEAN UROLOGY, 2013, 64 (05) : 799 - 810
  • [2] The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis
    Bhindi, Bimal
    Wallis, Christopher J. D.
    Boorjian, Stephen A.
    Thompson, R. Houston
    Farrell, Ann
    Kim, Simon P.
    Karam, Jose A.
    Capitanio, Umberto
    Golijanin, Dragan
    Leibovich, Bradley C.
    Gershman, Boris
    [J]. BJU INTERNATIONAL, 2018, 121 (05) : 684 - 698
  • [3] Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881
    Blom, Jan H. M.
    van Poppel, Hein
    Marechal, Jean M.
    Jacqmin, Didier
    Schroder, Fritz H.
    de Prijck, Linda
    Sylvester, Richard
    [J]. EUROPEAN UROLOGY, 2009, 55 (01) : 28 - 34
  • [4] D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
  • [5] 2-B
  • [6] Analysis of lymph node dissection in patients with ≥7-cm renal tumors
    Feuerstein, Michael A.
    Kent, Matthew
    Bazzi, Wassim M.
    Bernstein, Melanie
    Russo, Paul
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1531 - 1536
  • [7] Lymph node dissection during cytoreductive nephrectomy: A retrospective analysis
    Feuerstein, Michael A.
    Kent, Matthew
    Bernstein, Melanie
    Russo, Paul
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (09) : 874 - 879
  • [8] Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma
    Gershman, Boris
    Thompson, R. Houston
    Boorjian, Stephen A.
    Lohse, Christine M.
    Costello, Brian A.
    Cheville, John C.
    Leibovich, Bradley C.
    [J]. EUROPEAN UROLOGY, 2018, 74 (06) : 825 - 832
  • [9] Using observational data for personalized medicine when clinical trial evidence is limited
    Gershman, Boris
    Guo, David P.
    Dahabreh, Issa J.
    [J]. FERTILITY AND STERILITY, 2018, 109 (06) : 946 - 951
  • [10] Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis
    Gershman, Boris
    Thompson, R. Houston
    Boorjian, Stephen A.
    Larcher, Alessandro
    Capitanio, Umberto
    Montorsi, Francesco
    Carenzi, Cristina
    Bertini, Roberto
    Briganti, Alberto
    Lohse, Christine M.
    Cheville, John C.
    Leibovich, Bradley C.
    [J]. JOURNAL OF UROLOGY, 2018, 199 (05) : 1143 - 1148